8,485 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Eurizon SLJ Capital Ltd

Eurizon SLJ Capital Ltd acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, HoldingsChannel.com reports. The firm acquired 8,485 shares of the company’s stock, valued at approximately $5,740,000. IDEXX Laboratories makes up approximately 2.3% of Eurizon SLJ Capital Ltd’s portfolio, making the stock its 16th biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Beacon Investment Advisory Services Inc. increased its stake in IDEXX Laboratories by 11.9% during the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after acquiring an additional 6,710 shares during the last quarter. Nordea Investment Management AB increased its stake in IDEXX Laboratories by 114.1% during the fourth quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock worth $11,283,000 after acquiring an additional 8,845 shares during the last quarter. New York State Common Retirement Fund increased its stake in IDEXX Laboratories by 6.8% during the third quarter. New York State Common Retirement Fund now owns 60,225 shares of the company’s stock worth $38,477,000 after acquiring an additional 3,820 shares during the last quarter. Mediolanum International Funds Ltd increased its stake in IDEXX Laboratories by 14.5% during the third quarter. Mediolanum International Funds Ltd now owns 38,761 shares of the company’s stock worth $24,441,000 after acquiring an additional 4,909 shares during the last quarter. Finally, Procyon Advisors LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth $1,966,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president directly owned 18,141 shares of the company’s stock, valued at approximately $11,511,734.37. The trade was a 8.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.79% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on IDXX. Citigroup began coverage on IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 target price for the company. BTIG Research cut their target price on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. UBS Group cut their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Piper Sandler cut their target price on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research note on Monday, February 9th. Finally, Barclays cut their target price on IDEXX Laboratories from $850.00 to $800.00 and set an “overweight” rating for the company in a research note on Thursday, February 5th. Seven equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Trading Down 0.8%

Shares of NASDAQ IDXX opened at $563.53 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $504.56 and a twelve month high of $769.98. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a fifty day simple moving average of $564.58 and a 200-day simple moving average of $637.19. The stock has a market capitalization of $44.45 billion, a PE ratio of 41.50, a PEG ratio of 3.30 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the firm posted $2.91 earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.